Napabucasin (BBI608)

别名: BBI608

Napabucasin (BBI608) 是一种口服具有活性的Stat3和癌细胞多能性抑制剂。

Napabucasin (BBI608) Chemical Structure

Napabucasin (BBI608) Chemical Structure

CAS: 83280-65-3

规格 价格 库存 购买数量
10mM (1mL in DMSO) 958.23 现货
5mg 957.38 现货
25mg 3261.41 现货
100mg 8169.42 现货
1g 30876.3 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

Napabucasin (BBI608)相关产品

相关信号通路图

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
MDA-MB-231 Function assay 100 uM 1 hr Binding affinity to STAT3 in human MDA-MB-231 cells at 100 uM treated for 1 hr followed by thermolysin addition measured after 30 mins by DARTS-Western blot analysis 30003778
MDA-MB-231 Function assay 5 umol/L 24 hrs Induction of superoxide generation in human MDA-MB-231 cells at 5 umol/L measured after 24 hrs by DHE staining based flow cytometry 30003778
MDA-MB-231 Function assay 5 umol/L 24 hrs Induction of superoxide generation in human MDA-MB-231 cells at 5 umol/L measured after 24 hrs in presence of NQO1 inhibitor dicoumarol by DHE staining based flow cytometry 30003778
human HaCaT cells Function assay 48 h Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy, IC50=0.5 μM 22845014
human DU145 cells Function assay 72 h Anticancer activity against human DU145 cells after 72 hrs by XTT assay, IC50=0.02304 μM 18829316
MDA-MB-231 Cytotoxicity assay 72 hrs Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.34 μM. 28558333
HepG2 Cytotoxicity assay 72 hrs Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.66 μM. 28558333
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.74 μM. 28558333
K562 Antiproliferative assay 48 hrs Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay, IC50 = 1 μM. 30003778
MDA-MB-231 Function assay 4 hrs Inhibition of STAT3 phosphorylation at Y705 in human MDA-MB-231 cells assessed as reduction in ratio of phosphorylated STAT3 to total STAT3 level after 4 hrs by HTRF assay, EC50 = 1.9 μM. 30003778
MDA-MB-231 Function assay 4 hrs Inhibition of STAT3 phosphorylation at Y705 in human MDA-MB-231 cells after 4 hrs by HTRF assay, EC50 = 2 μM. 30003778
MDA-MB-231 Antiproliferative assay 48 hrs Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay, IC50 = 2.1 μM. 30003778
HepG2 Antiproliferative assay 48 hrs Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay, IC50 = 10.2 μM. 29604543
L02 Antiproliferative assay 48 hrs Antiproliferative activity against human L02 cells after 48 hrs by CCK-8 assay, IC50 = 18.7 μM. 29604543
human HaCaT cells Proliferation assay Antiproliferative activity against human HaCaT cells, IC50=0.5 μM 10479319
KB cells Cytotoxicity assay Effective cytotoxic dose against KB cells was evaluated, ED50=4.2 μM 9873618
点击查看更多细胞系数据

生物活性

产品描述 Napabucasin (BBI608) 是一种口服具有活性的Stat3和癌细胞多能性抑制剂。
靶点
Stat3 [1]
体外研究(In Vitro)
体外研究活性 Napabucasin下调Stat3驱动的干细胞基因表达和癌症干细胞性能,并有效抑制高度多功能性癌细胞的自我更新,IC50范围为0.291~1.19 μM,而对正常干细胞没有抑制作用。[1]
细胞实验 细胞系 肿瘤干细胞 U87-MG,U118,COLO205,DLD1,SW480,HCT116,FaDu,ACHN,SNU-475,Huh7,HepG2,H1975,A549,H460,CAOV-3,SW-626,PaCa2
浓度 ~2 μM
孵育时间 72小时
方法

对于各种癌症干细胞,将球体解离,并在癌症干细胞培养条件下接种到镀层96孔板。培养72小时后,孔中加入指示剂量的化合物。加入72小时或24小时后,将CellTiter-Glo 2.0加入每个孔,荧光根据制造商的描述测量。IC50值使用GraphPad Prism软件通过将四参数剂量响应曲线拟合到标准数据计算。大部分细胞以5,000细胞/孔接种到96孔板。接种24小时后,细胞用指示浓度的化合物处理。存活率在72小时根据如上所述测定。

实验图片 检测方法 检测指标 实验图片 PMID
Western blot CDK4 / Cyclin D1 STAT3 / β-catenin / c-Myc c-Myc / Nanog / Bmi-1 / Axl / Sox2 / Klf4 / β-catenin / Survivin 31277685
Immunofluorescence STAT3 Cleaved caspase-3 31277685
Growth inhibition assay Cell viability 31277685
体内研究(In Vivo)
体内研究活性 在负荷PaCa-2异种移植物的小鼠中,Napabucasin (20 mg/kg, i.p.)显著抑制肿瘤生长,复发和转移。[1]
动物实验 Animal Models 负荷 PaCa-2 移植物的小鼠
Dosages 20 mg/kg
Administration i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03525405 Completed
ADME|Healthy
Sumitomo Pharma America Inc.
May 18 2018 Phase 1
NCT03416816 Terminated
Neoplasms
Sumitomo Pharma America Inc.|Syneos Health
May 15 2018 Phase 1
NCT02279719 Completed
Hepatocellular Carcinoma
Sumitomo Pharma America Inc.
December 2014 Phase 1|Phase 2

化学信息&溶解度

分子量 240.21 分子式

C14H8O4

CAS号 83280-65-3 SDF Download Napabucasin (BBI608) SDF
Smiles CC(=O)C1=CC2=C(O1)C(=O)C3=CC=CC=C3C2=O
储存条件(自收到货起)

体外溶解度
批次:

DMSO : 14 mg/mL ( (58.28 mM) ;DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy Napabucasin (BBI608) | Napabucasin (BBI608) supplier | purchase Napabucasin (BBI608) | Napabucasin (BBI608) cost | Napabucasin (BBI608) manufacturer | order Napabucasin (BBI608) | Napabucasin (BBI608) distributor
在线咨询
联系我们